Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS Licenses SYNtecan Linker-Payload Platform from Lonza | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

BMS Licenses SYNtecan Linker-Payload Platform from Lonza

Will help advance an ADC against an undisclosed target.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Lonza, a contract development and manufacturing organization (CDMO), and Bristol Myers Squibb, a global pharmaceutical company dedicated to discovering, developing and delivering innovative medicines, have entered an exclusive single-target licensing agreement under which BMS will gain exclusive access to the SYNtecan linker-payload platform to advance an ADC against an undisclosed target.

BMS will perform the research, development, manufacturing and commercialization of the ADC. Lonza, through one of its affiliated companies, will be eligible to receive upfront, potential milestone payments and royalty payments on net sales of resulting products.

Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis, Lonza, said, “BMS has long been at the forefront of innovation in our industry, and this agreement marks a significant achievement in our collaboration with BMS.

According to Vertommen, licensing SYNtecan linker-payloads, Lonza’s TOPO1 inhibitor platform, to BMS provides another strong validation of its strength and its trustworthiness in delivering positive clinical outcomes.

He added, “We are pleased to add BMS to our partnered pipeline, as we collaborate to advance therapies that provide meaningful treatments to individuals who are still facing a critical unmet medical need.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics